Engineered immune cells take aim at childhood cancer in new trial
Disease control
Recruiting now
This study tests a new treatment for children and young adults with high-risk neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called ALK found o…
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated May 15, 2026 11:57 UTC